Global Care Capital Forum: Community User: Schnuffel

ViraxClear has received initial orders for trials and market testing of their Test Kits for the Chilean market and manufacturing is expected to commence over the next 60 days. The LOI provides for a 60-day exclusivity period during which ViraxClear and Biosonda intend to sign a definitive agreement with a total contract value of up to $17.25 million.

As a major investment into the healthcare sector, ViraxClear presents a tremendous opportunity. The novel coronavirus has become a worldwide pandemic that requires serious intervention for countries to return to status quo. The Company is not making KEY INVESTMENT PORTFOLIO DESCRIPTION (continued) ViraxClear Rapid Test Corp. (continued) any express or implied claims that it has the ability to treat the COVID-19 virus at this time. ViraxClear is a start-up company in the newly created COVID-19 antibody test market and has commenced sales and distribution of its test kits in Mexico. As a distributor, ViraxClear’s focus on commercialization targets the marketing and distribution portion of the value chain. ViraxClear’s manufacturing partner, Shanghai Liangrun Biomedicine Technology Co., Ltd., has production capacity of one million test kits per week at their factory in Shanghai, China. On April 20, 2020, ViraxClear, obtained Emergency Use Authorization (EUA) by the Food and Drug Administration (“FDA”) for the COVID-19 test kits it distributes and markets. ViraxClear’s tests can be used by clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA). ViraxClear’s COVID-19 test kit also has CE marking allowing sales to the European Community, and to other global markets that accept a CE marking as valid regulatory approval following routine local product registration. On May 5, 2020, ViraxClear finalized supply contracts with Shenzhen Qianhai Huolilang Technology Co., Ltd. (“Qianhai”) for the supply of KN95 Masks manufactured by Promask Electronic Medical Device (Guangzhou) Manufacturing Co., Ltd. globally. On May 13, 2020, ViraxClear signed a letter of intent for the distribution of its COVID-19 Rapid Antibody Test Kits (the “Test Kits”) for Morocco. On May 20, 2020, ViraxClear finalized a Letter Of Intent with Phyto Pharma Ltd, for the supply of 5,000 FDA Registered and CE marked infrared thermometer units for sale in North America, with a Purchase Order signed for the value of US$125,000 for the 5,000 units. On June 10, 2020, the Company announced that ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd., (“SBD”) has now launched its Employee Protection Equipment (“EPE”) kit, which will help business owners protect their employees from the transmission of Virax infections, such as COVID-19. ViraxClear will distribute the EPE kits through its newly launched sales platform, ViraxCare, www.viraxcare.com. On June 25, 2020, the Company announced that ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd., received its approval certificate from the Philippines Food and Drug Administration (“PFDA”) for the distribution of COVID19 Rapid Antibody Test Kits (“Test Kits”) for the Philippines market with a contract valued at up to $7,500,000 in gross sales for the distribution of up to 1,000,000 Test Kits for the Philippines. Following PFDA approval, Philippines medical device distribution company Novarad Asia Pacific Company has become ViraxClear’s exclusive distribution partner for the Philippines for ViraxClear Test Kits. The full contract is worth up to $7,500,000, over a 1 year period. The PFDA requires test kits to be on their approved list before being allowed through customs for sale in the country. ViraxClear tests have been approved in collaboration with Hangzhou Clongene Biotech Ltd., the ViraxClear manufacturing partner for the Philippines region. On July 7, 2020, the Company announced that its portfolio company, ViraxClear, through its joint venture, SBD has received approval on July 3rd, 2020 from El Instituto de Salud Pública de Chile (“ISP”) for the distribution of COVID-19 Rapid Antibody Test Kits supplied by its previously disclosed manufacturing partners, Innovita Biological Technology Co. Ltd, and Vazyme Biotech Co., Ltd (“Innovita”, “Vazyme”), for the Chilean market. ViraxClear has signed a non-binding Letter Of Intent (“LOI”) with Biosonda Biotecnologia (“Biosonda”) for the distribution of up to 3,000,000 Test Kits for the Chilean market, a contract valued at up to $17.25 million in gross revenue.

OPERATIONAL HIGHLIGHTS (continued) Investment Acquisitions (continued) Reformation Pharmaceuticals Corp. On June 30, 2020, the Company completed the sale of all of the issued and outstanding shares of its wholly-owned subsidiary ReFormation Pharmaceuticals Corp. ("ReFormation") to 360 Life Sciences Corp. (the "Purchaser") pursuant to the share purchase agreement between Global Care and the Purchaser signed on June 24, 2020. The Purchaser acquired all the issued and outstanding shares of ReFormation in exchange for 800,000 common shares of the Purchaser. Share consolidation On March 13, 2020, the Company completed a share consolidation of its share capital on a 25:1 basis. As a result of the share consolidation, the 122,331,000 common shares issued and outstanding were consolidated to 4,893,235 common shares. All common shares and per share amounts have been restated to give effect to the share consolidation. Resignations and appointment On January 13, 2020, the Company announced the resignations of Mr. Theo. van der Linde as Chief Financial Officer and Mr. Eugene Beukman as Corporate Secretary. The Company would like to thank Messrs. van der Linde and Beukman for their contributions to the Company and wishes them well in their future endeavours. On April 15, 2020, the Company announced the appointment of Mr. James Henning as Chief Financial Officer. James Henning is a Chartered Professional Accountant and the Founder and President of Corpfinance Advisors Inc. since 1984. Mr. Henning has solid expertise and practical experience in valuating businesses in a broad range of industries. He has assisted companies in financing, public offerings, and restructuring. Areas of expertise include manufacturing, telecommunications, software, biomedical, oil & gas services and renewable energy industries. Mr. Henning has served as a Chief Financial Officer and Director for a number of TSX Venture Exchange and Canadian Securities Exchange listed companies over the past several years. Company name and symbol changes On April 15, 2020, the Company changed its name from Resinco Capital Partners Inc. to Global Care Capital Inc. Effective April 17, 2020, the Company’s common shares began trading under the new name and the ticker symbol “HLTH” on the Canadian Securities Exchange. The Company engaged in due diligence and research procedures in search of new, early stage investment opportunities in the healthcare sector to diversify and strengthen its existing portfolio. The name and ticker symbol change reflect an initiative to align the Company brand with this new strategic focus. KEY INVESTMENT PORTFOLIO DESCRIPTION ViraxClear Rapid Test Corp. Pursuant to the terms of the Share Purchase Agreement with ViraxClear, Global Care Capital issued 24,000,000 common shares of the Company (each a “Consideration Share”) to vendors in return for a 100% interest in ViraxClear. At closing, the ViraxClear option holders exchanged their outstanding ViraxClear options (the “ViraxClear Options”) for replacement Global Care Capital options (each a “Global Care Capital Option”). Each ViraxClear Option was exchanged for a Global Care Capital Option on a 1:1 basis for an aggregate of 2,900,000 Global Care Capital Options. Of the aggregate number of Global Care Capital Options to be issued, 2,400,000 Global Care Capital Options have an exercise price of $0.50 per Global Care Capital common share until April 15, 2022; and 500,000 Global Care Capital Options have an exercise price of $0.20 per Global Care Capital common share until April 15, 2022.

INTRODUCTION The following management discussion and analysis – quarterly highlights (“MD&A – Quarterly Highlights”) of the results of operations and financial condition of Global Care Capital Inc. (formerly Resinco Capital Partners Inc.) (“Global” or the “Company”) for the six months ended June 30, 2020 and up to the date of this MD&A – Quarterly Highlights, has been prepared to provide material updates to the business operations, financial condition, liquidity and capital resources of the Company since its last management discussion and analysis for the year ended December 31, 2019 (the “Annual MD&A”) This MD&A – Quarterly Highlights should be read in conjunction with the Annual MD&A and the audited financial statements for the year ended December 31, 2019, together with the notes thereto, and the accompanying unaudited condensed interim financial statements and related notes thereto for the six months ended June 30, 2020 (the “Financial Report”). All financial information in this MD&A – Quarterly Highlights is derived from the Company’s financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) and all dollar amounts are expressed in Canadian dollars unless otherwise indicated. The effective date of this MD&A – Quarterly Highlights is August 31, 2020. DESCRIPTION OF BUSINESS Global was incorporated under the laws of British Columbia on May 25, 2004. The Company’s shares are listed for trading on the Canadian Securities Exchange (“CSE”) under the ticker symbol “RIN”, the Frankfurt Stock Exchange under the symbol L6V1.F and on the United States OTC stock market’s OTC Pink, under the symbol RSCZF. The registered office of the Company is Suite 810 – 789 West Pender Street, Vancouver, British Columbia, Canada, V6C 1H2. Global is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile. In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. The impact on the Company is not currently determinable but management continues to monitor the situation. OPERATIONAL HIGHLIGHTS Investment Acquisitions ViraxClear Rapid Test Corp. On April 17, 2020, the Company acquired all of the issued and outstanding shares of ViraxClear Rapid Test Corp. d/b/a ViraxClear (“ViraxClear”).. ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test and ViraxCare PPE. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies. ViraxCare is aimed at minimizing at-work risks by supplying PPE for employees and innovative products and devices which monitor potential viral outbreaks. High Standard Health Care Ltd. On June 5, 2020, the Company acquired 70% of High Standard Health Care Ltd. (“HSHC”) in exchange for 27,000,000 of the Company’s common shares. High Standard Health Care is a leading global PPE provider assisting front line workers during the global pandemic. To date the company has procured respiratory masks, gowns, hand sanitizer, infrared thermometers, and face shields. To date High Standard Health Care customers, include hospitals, schools, municipalities, long-term care facilities, fire departments and police departments.

Kann den link nicht öffnen was Steht den da genau drinnen?

Die haben auch bis zum letzten Tag gewartet 😁

Man muss den Verification-Code bestätigen, um die einzelnen Dokumente zu öffnen und zu lesen

https://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo=00021175&issuerType=03&projectNo=03108162&docId=4791437

Sorry kann ich nicht öffnen 😣

Bericht 31.08. auf SEDAR.com !!! Suche nach Global Care Capital dort steht der Abschluss javascript:submitFiling(document.form1598900468838,'AcceptTermsOfUse');

Im Nachhinein ist man immer schlauer, sollte man zumindestens. Zum Glück habe ich keine hohen Summen investiert.

Was ich aus der Sache gelernt habe: Nie im Aufwärtshype kaufen. Wenn eine Aktie so hochgeht wie diese im Mai, dann in die Watchlist und mal sehen was passiert. Wenn das Ding gefallen ist und sich nicht mehr rührt, dann damit beschäftigen, ob es handfeste Werte gibt (wie hier Quartalszahlen).

Die haben ja noch bis zum 31.08 Zeit die Verhandlungen zu verkünden. Dann kann ja der ein oder andere den Schub nutzen 👍

Danke Blender. Überlege noch, leider habe ich kein Goldesel, möchte aber auch nicht das Geld aus den Fenster werfen. Keine Antwort klingt plausibel.

Jup habe einiges vom Polly

Oh Mann, das ist hart.